Rapid metachronous bladder metastasis of type 2 papillary renal cell carcinoma
Abstract
##plugins.themes.bootstrap3.article.details##
Renal cell carcinoma, Bladder metastasis, Papillary cell
2. Wagener N, Edelmann D, Benner A, et al. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease. Plos one. 2017;12(9):e0184173. DOI: 10.1371/journal.pone.0184173. PMID: 28934212; PMCID: PMC5608215.
3. Kim JY, Jeong HO, Heo DS, et al. Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data. Ann Transl Med. 2020;8(21):1389. doi: 10.21037/atm-20-3466. PMID: 33313134; PMCID: PMC7723617.4.
4. Nayak JG, Patel P, Bjazevic J, et al. Clinical outcomes following laparoscopic management of pT3 renal masses: A large, multi-institutional cohort. Can Urol Assoc J. 2015;9(11-12):397-402. doi: 10.5489/cuaj.2848. PMID: 26788228; PMCID: PMC4707891.
5. Chin AI, Lam JS, Figlin RA, Belldegrun AS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol. 2006;8(1):1-7. PMID: 16985554; PMCID: PMC1471767.
6. Dabestani S, Thorstenson A, Lindblad P, et al. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol. 2016;34(8):1081-1086. doi: 10.1007/s00345-016-1773-y. PMID: 26847337.
7. Macedo-Alves D, Koch P, Soares V, et al. Thyroid metastasis from renal cell carcinoma-A case report after 9 years. Int J Surg Case Rep. 2015;16:59-63. doi: 10.1016/j.ijscr.2015.09.004. PMID: 26421840; PMCID: PMC4643339.
8. Grassi P, Doucet L, Giglione P, et al. Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. PLoS One. 2016;11(4):e0151662. doi: 10.1371/journal.pone.0151662. PMID: 27064898; PMCID: PMC4827845.
9. Ferhatoglu MF, Senol K, Filiz AI. Skin Metastasis of Renal Cell Carcinoma: A Case Report. Cureus. 2018;10(11):e3614. doi: 10.7759/cureus.3614. PMID: 30680270; PMCID: PMC6340412.
10. Ihsen Z, Khadija M, Zouhayer J, et al. Cardiac metastasis from a renal cell carcinoma. Pan Afr Med J. 2015;22:167. doi: 10.11604/pamj.2015.22.167.7130. PMID: 26893801; PMCID: PMC4747446.
11. Arpita S, Manoj J, Kaushik S, Anish S. Metastasis of renal cell carcinoma to urinary bladder: A rare case report with review of literature. J Lab Physicians. 2017;9(4):322-324. doi: 10.4103/JLP.JLP_108_16. PMID: 28966499; PMCID: PMC5607766.
12. Matsumoto K, Hayakawa N, Nakamura S, Oya M. Bladder metastasis from renal cell carcinoma: retrospective analysis of 65 reported cases. Clin Exp Metastasis. 2015;32(2):135-141. doi: 10.1007/s10585-015-9698-1. PMID: 25630270.
13. Kassouf W, Monteiro LL, Drachenberg DE, et al. Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma. Can Urol Assoc J. 2018;12(8):231-238. doi: 10.5489/cuaj.5462. PMID: 30139427; PMCID: PMC6114161.
14. Xiong S, Zhu W, Li X, et al. Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis. Transl Androl Urol. 2021;10(8):3255-3266. doi: 10.21037/tau-21-329. PMID: 34532250; PMCID: PMC8421816.
15. Warrick JI, Tsodikov A, Kunju LP, et al. Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations. Hum Pathol. 2014;45(6):1139-1146. doi: 10.1016/j.humpath.2014.02.004. PMID: 24767860; PMCID: PMC6180318.
16. Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: A Review. JAMA. 2020;324(19):1980-1991. doi: 10.1001/jama.2020.17598. PMID: 33201207.
17. Wollin T, Laroche B, Psooy K. Canadian guidelines for the management of asymptomatic microscopic hematuria in adults. Can Urol Assoc J. 2009;3(1):77-80. doi: 10.5489/cuaj.1029. PMID: 19293985; PMCID: PMC2645872.
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.